Back to Search
Start Over
Conventional CARs versus modular CARs
- Source :
- Cancer Immunology, Immunotherapy 68(2019)10, 1713-1719, Cancer Immunology, Immunotherapy
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- The clinical application of immune effector cells genetically modified to express chimeric antigen receptors (CARs) has shown impressive results including complete remissions of certain malignant hematological diseases. However, their application can also cause severe side effects such as cytokine release syndrome (CRS) or tumor lysis syndrome (TLS). One limitation of currently applied CAR T cells is their lack of regulation. Especially, an emergency shutdown of CAR T cells in case of life-threatening side effects is missing. Moreover, targeting of tumor-associated antigens (TAAs) that are not only expressed on tumor cells but also on vital tissues requires the possibility of a switch allowing to repeatedly turn the activity of CAR T cells on and off. Here we summarize the development of a modular CAR variant termed universal CAR (UniCAR) system that promises to overcome these limitations of conventional CARs.
- Subjects :
- 0301 basic medicine
Cancer Research
T-Lymphocytes
medicine.medical_treatment
Immunology
T cells
Tumor cells
TIMO XIV
Immunotherapy, Adoptive
UniCAR
BiTE
03 medical and health sciences
0302 clinical medicine
Antigen
Neoplasms
medicine
Humans
Immunology and Allergy
Chimeric antigen receptor
Receptors, Chimeric Antigen
business.industry
Immunotherapy
Modular design
medicine.disease
Tumor lysis syndrome
Cytokine release syndrome
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Focussed Research Review
Cancer research
Car t cells
business
human activities
Subjects
Details
- ISSN :
- 14320851 and 03407004
- Volume :
- 68
- Database :
- OpenAIRE
- Journal :
- Cancer Immunology, Immunotherapy
- Accession number :
- edsair.doi.dedup.....8e9317bacac58782ff09beb3e65abd6c